title: Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia.
authors.forename: Georgia
authors.initials: G
authors.lastname: Lazaraki
authors.forename: Evangelos
authors.initials: E
authors.lastname: Akriviadis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Pilpilidis
authors.forename: Ioanna
authors.initials: I
authors.lastname: Parisi
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Tzilves
authors.forename: Anestis
authors.initials: A
authors.lastname: Tarpangos
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D016099:Endoscopy, Gastrointestinal; D004844:Epistaxis / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy*; D041981:Gastrointestinal Tract / Q000473:pathology; D006801:Humans; D007501:Iron / Q000008:administration & dosage; D008099:Liver / Q000002:abnormalities; D055502:Secondary Prevention; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D007501:Iron